Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia

Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia

Introduction: Ramucirumab (Ram), a human IgG 1 antibody against vascular endothelial growth factor receptor 2. This multicenter retrospective study aims to reviewed the results of Ram-based therapy as second-line treatment in patients with advanced gastric cancer in a real-life setting.Methods: it w...

Full description

Bibliographic Details
Main Authors: N. S. Besova, T. A. Titova, E. V. Artamonova, D. L. Stroyakovskiy, E. V. Perminova, D. Yu. Yukal’chuk, D. M. Ponomarenko, N. P. Belyak, R. V. Orlova, G. M. Teletaeva, E. Yu. Ratner, A. S. Mochalova, O. O. Gordeeva, A. S. Zhabina, S. V. Gamayunov, A. V. Smolin, A. Yu. Povyshev, M. I. Andrievskikh, A. A. Tryakin, I. S. Stilidi
Format: Article
Language:Russian
Published: Remedium Group LLC 2019-12-01
Series:Медицинский совет
Subjects:
ramucirumab
gastric cancer
irinotecan
fluoropyrimidine adenocarcinoma
second line treatment
Online Access:https://www.med-sovet.pro/jour/article/view/5238

Internet

https://www.med-sovet.pro/jour/article/view/5238

Similar Items